TY - JOUR
T1 - UFM1 founder mutation in the Roma population causes recessive variant of H-ABC
AU - Hamilton, Eline M.C.
AU - Bertini, Enrico
AU - Kalaydjieva, Luba
AU - Morar, Bharti
AU - Dojčáková, Dana
AU - Liu, Judy
AU - Vanderver, Adeline
AU - Curiel, Julian
AU - Persoon, Claudia M.
AU - Diodato, Daria
AU - Pinelli, Lorenzo
AU - Van Der Meij, Nathalie L.
AU - Plecko, Barbara
AU - Blaser, Susan
AU - Wolf, Nicole I.
AU - Waisfisz, Quinten
AU - Abbink, Truus E.M.
AU - Van Der Knaap, Marjo S.
PY - 2017/10/24
Y1 - 2017/10/24
N2 - Objective: To identify the gene defect in patients with hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) who are negative for TUBB4A mutations. Methods: We performed homozygosity mapping and whole exome sequencing (WES) to detect the disease-causing variant. We used a Taqman assay for population screening.We developed a luciferase reporter construct to investigate the effect of the promoter mutation on expression. Results: Sixteen patients from 14 families from different countries fulfilling the MRI criteria for H-ABC exhibited a similar, severe clinical phenotype, including lack of development and a severe epileptic encephalopathy. The majority of patients had a known Roma ethnic background. Single nucleotide polymorphism array analysis in 5 patients identified one large overlapping homozygous region on chromosome 13. WES in 2 patients revealed a homozygous deletion in the promoter region of UFM1. Sanger sequencing confirmed homozygosity for this variant in all 16 patients. All patients shared a common haplotype, indicative of a founder effect. Screening of 1,000 controls from different European Roma panels demonstrated an overall carrier rate of the mutation of 3%-25%. Transfection assays showed that the deletion significantly reduced expression in specific CNS cell lines.
AB - Objective: To identify the gene defect in patients with hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) who are negative for TUBB4A mutations. Methods: We performed homozygosity mapping and whole exome sequencing (WES) to detect the disease-causing variant. We used a Taqman assay for population screening.We developed a luciferase reporter construct to investigate the effect of the promoter mutation on expression. Results: Sixteen patients from 14 families from different countries fulfilling the MRI criteria for H-ABC exhibited a similar, severe clinical phenotype, including lack of development and a severe epileptic encephalopathy. The majority of patients had a known Roma ethnic background. Single nucleotide polymorphism array analysis in 5 patients identified one large overlapping homozygous region on chromosome 13. WES in 2 patients revealed a homozygous deletion in the promoter region of UFM1. Sanger sequencing confirmed homozygosity for this variant in all 16 patients. All patients shared a common haplotype, indicative of a founder effect. Screening of 1,000 controls from different European Roma panels demonstrated an overall carrier rate of the mutation of 3%-25%. Transfection assays showed that the deletion significantly reduced expression in specific CNS cell lines.
UR - http://www.scopus.com/inward/record.url?scp=85031405215&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000004578
DO - 10.1212/WNL.0000000000004578
M3 - Article
C2 - 28931644
AN - SCOPUS:85031405215
SN - 0028-3878
VL - 89
SP - 1821
EP - 1828
JO - Neurology
JF - Neurology
IS - 17
ER -